999 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
PFE Pfizer, Inc. $43.01 $252.13B N/A
Article Searches
Merck's Keytruda Improves 5-Year Survival in Lung Cancer http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-ZC-FT-423872 Jun 03, 2019 - Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
Dow 30 Stock Roundup: BA's Dreamliner Order, MSFT LinkedIn's Drawbridge Buyout Plan http://www.zacks.com/stock/news/422744/dow-30-stock-roundup-bas-dreamliner-order-msft-linkedins-drawbridge-buyout-plan?cid=CS-ZC-FT-422744 May 31, 2019 - The index endured another tough week as investors braced for an economic slowdown.
This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy https://www.fool.com/investing/2019/05/28/this-just-in-goldman-sachs-picks-4-big-pharma-stoc.aspx?source=iedfolrf0000001 May 28, 2019 - And the analyst really likes one in particular.
Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study http://www.zacks.com/stock/news/420063/pfizers-pfe-epilepsy-drug-lyrica-fails-in-phase-iii-study?cid=CS-ZC-FT-420063 May 27, 2019 - Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.
3 Stocks to Win Big in the Fight Against Cancer http://www.zacks.com/stock/news/418995/3-stocks-to-win-big-in-the-fight-against-cancer?cid=CS-ZC-FT-418995 May 24, 2019 - We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint http://www.zacks.com/stock/news/417631/oculars-glaucoma-drug-study-fails-to-meet-primary-endpoint?cid=CS-ZC-FT-417631 May 21, 2019 - Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs http://www.zacks.com/stock/news/415516/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs?cid=CS-ZC-FT-415516 May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Pfizer's Eczema Candidate Meets All Goals in Phase III Study http://www.zacks.com/stock/news/414939/pfizers-eczema-candidate-meets-all-goals-in-phase-iii-study?cid=CS-ZC-FT-414939 May 16, 2019 - Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer http://www.zacks.com/stock/news/414385/pfizers-bavencio%2Binlyta-combo-gets-fda-nod-for-kidney-cancer?cid=CS-ZC-FT-414385 May 15, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug http://www.zacks.com/stock/news/412433/pharma-stock-roundup-agn-nvo-report-q1-earnings-nvs-to-buy-takedas-eye-drug?cid=CS-ZC-FT-412433 May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.

Pages: 12345678...100

<<<Page 3>